CN117618277A - Nursing method, nursing system and application of synergistic effect of red light and composition - Google Patents
Nursing method, nursing system and application of synergistic effect of red light and composition Download PDFInfo
- Publication number
- CN117618277A CN117618277A CN202211195119.XA CN202211195119A CN117618277A CN 117618277 A CN117618277 A CN 117618277A CN 202211195119 A CN202211195119 A CN 202211195119A CN 117618277 A CN117618277 A CN 117618277A
- Authority
- CN
- China
- Prior art keywords
- care
- red light
- composition
- tripeptide
- biotin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 22
- 230000000474 nursing effect Effects 0.000 title abstract description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 112
- 229960002685 biotin Drugs 0.000 claims abstract description 56
- 235000020958 biotin Nutrition 0.000 claims abstract description 56
- 239000011616 biotin Substances 0.000 claims abstract description 56
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 52
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 36
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 36
- 102000012422 Collagen Type I Human genes 0.000 claims abstract description 35
- 108010022452 Collagen Type I Proteins 0.000 claims abstract description 35
- 230000001737 promoting effect Effects 0.000 claims abstract description 15
- 230000003656 anti-hair-loss Effects 0.000 claims abstract description 11
- 230000003779 hair growth Effects 0.000 claims description 10
- 210000004761 scalp Anatomy 0.000 claims description 10
- 238000005286 illumination Methods 0.000 claims description 9
- 239000002324 mouth wash Substances 0.000 claims description 8
- 229940051866 mouthwash Drugs 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000002407 ATP formation Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000551 dentifrice Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229940041672 oral gel Drugs 0.000 claims description 3
- 229940041678 oral spray Drugs 0.000 claims description 3
- 239000000668 oral spray Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 239000013543 active substance Substances 0.000 abstract description 11
- 230000003712 anti-aging effect Effects 0.000 abstract description 11
- 201000004384 Alopecia Diseases 0.000 abstract description 8
- 239000013588 oral product Substances 0.000 abstract description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 33
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 23
- 108010035532 Collagen Proteins 0.000 description 23
- 229920001436 collagen Polymers 0.000 description 23
- 239000000284 extract Substances 0.000 description 20
- 239000011259 mixed solution Substances 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 19
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000032683 aging Effects 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940082500 cetostearyl alcohol Drugs 0.000 description 8
- 230000003658 preventing hair loss Effects 0.000 description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 8
- -1 polyethylene Polymers 0.000 description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 7
- 235000010234 sodium benzoate Nutrition 0.000 description 7
- 239000004299 sodium benzoate Substances 0.000 description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229940041616 menthol Drugs 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 5
- 241000218628 Ginkgo Species 0.000 description 5
- 235000011201 Ginkgo Nutrition 0.000 description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000004088 foaming agent Substances 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 3
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000546273 Lindera <angiosperm> Species 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000221095 Simmondsia Species 0.000 description 3
- 235000004433 Simmondsia californica Nutrition 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229930007927 cymene Natural products 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 238000009636 ATP test Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 240000002924 Platycladus orientalis Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 210000000003 hoof Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- WSELJKAMVUHMJP-PUZYILPLSA-N (2s,3r,4s,5r)-2,3-dichloro-2,3,4,5,6-pentahydroxyhexanoyl chloride Chemical compound OC[C@@H](O)[C@H](O)[C@@](O)(Cl)[C@](O)(Cl)C(Cl)=O WSELJKAMVUHMJP-PUZYILPLSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000005740 Boscalid Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- JBBRZDLNVILTDL-XNTGVSEISA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 16-methylheptadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC(C)C)C1 JBBRZDLNVILTDL-XNTGVSEISA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 description 1
- 229940118790 boscalid Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
The application discloses a nursing method, nursing system and application of synergistic effect of red light and a composition, and relates to the technical fields of skin care products, oral products and anti-hair-loss and hair-growing products, wherein the nursing method comprises the following steps: applying the composition to a care area; illuminating the care area with a red light source; wherein the composition comprises biotin and tripeptide-1. The application has the effect of synergistically promoting the synthesis of collagen I by combining efficacy active substances (biotin and tripeptide-1) and low-energy red light (LLLT); and, has the effect of synergistically promoting the generation of ATP; it is demonstrated that the combination of low energy red light and efficacy actives has a synergistic effect on anti-aging, anti-alopecia and oral care.
Description
Technical Field
The application relates to the technical fields of skin care products, oral products and anti-hair loss and hair growth products, in particular to a nursing method, a nursing system and application of synergistic effect of red light and a composition.
Background
With the aging, ultraviolet irradiation and irregular life work, the collagen of the human body can gradually reduce loss, which is an important expression of the aging of the human body. Collagen loss can cause problems with hair, chest, endocrine system, reproductive system, eyes and skin. Mainly shows dry and forked hair, alopecia, baldness, skin depression, wrinkle increase, pore increase and the like. There are two main approaches to preventing collagen loss, one is to reduce the rate of collagen loss, and the other is to supplement collagen and stimulate collagen production by oral or external administration. The oral administration is generally to eat foods rich in collagen or health care products rich in collagen, such as cow hooves, pig hooves or fish jelly. The external use is generally to use a skin care product containing a collagen component or a component promoting collagen synthesis. Preventing collagen loss, supplementing and stimulating collagen generation, and can effectively help people resist aging and alopecia, thereby achieving the effects of resisting aging and preventing alopecia.
Disclosure of Invention
The application provides a nursing method, nursing system and application of synergistic effect of red light and a composition, which utilize low-energy red light (LLLT) and efficacy active substances (biotin and tripeptide-1) to combine and match and synergistically improve the synthesis amount of collagen I and the generation amount of Adenosine Triphosphate (ATP) in cells, realize the anti-aging and anti-hair-loss effects, and can be applied to skin care products, cosmetics, oral care products, personal care products and anti-hair-loss products.
In a first aspect, the present application provides a method of care for a synergistic effect of red light and a composition, the method of care comprising: applying the composition to a care area; illuminating the care area with a red light source; wherein the composition comprises biotin and tripeptide-1.
It should be noted that there is no sequence of two steps in the care method, and as an example, the composition may be applied to the care area first and then irradiated with the red light source as described above; in another example, the composition may be applied to the care area after the care area is irradiated with a red light source; in other examples, the application of the composition to the care area may also be performed simultaneously with the irradiation of the care area with the red light source, and the application is not strictly limited according to the specific choice of the actual situation.
In some embodiments, the biotin and tripeptide-1 are present in an amount of 0.01wt% to 20wt% based on the total weight of the composition.
In some embodiments, the biotin and tripeptide-1 are present in an amount of 0.1wt% to 7wt% based on the total weight of the composition.
In some embodiments, the mass concentration ratio of biotin to tripeptide-1 is 1 (0.3-3).
In some embodiments, the mass concentration ratio of biotin to tripeptide-1 is 1:1.
in some embodiments, the wavelength of the red light source is 600nm to 760nm; the illumination dosage of the red light source is 1J/cm 2 To 50J/cm 2 。
In some embodiments, the wavelength of the red light source is 600nm to 660nm; the illumination dosage of the red light source is 1J/cm 2 To 20J/cm 2 。
In some embodiments, the obtaining device of the red light source comprises at least one of an LED generating device and a laser generating device.
In a second aspect, the present application provides a red light synergistic care system comprising a red light source and a composition; the combination system is for use in the care method of any one of the above.
In a third aspect, the present application provides the use of a method of care as defined in any one of the preceding claims or a care system as defined in any one of the preceding claims in skin care, hair loss prevention, oral care.
In some embodiments, if the method of care or the care system is applied to skin care, the composition is present in any one of a lotion, a concentrate, an emulsion, a cream, or a mask;
if the method of care or the system of care is applied to anti-hair loss and hair growth, the composition is present in any of a shampoo, a conditioner, scalp essence, or scalp spray;
if the method of care or the care system is applied to oral care, the composition is in any of a toothpaste, a dentifrice, a mouthwash, an oral spray, an oral dressing, or an oral gel.
In a fourth aspect, the present application provides the use of a method of care as defined in any one of the preceding claims or a care system as defined in any one of the preceding claims for promoting synthesis of collagen I.
In a fifth aspect, the present application provides the use of a method of care as defined in any one of the preceding claims or a care system as defined in any one of the preceding claims to promote the production of ATP.
Compared with the prior art, the invention has the following beneficial effects:
(1) The combination system comprises a red light source and a composition, wherein the red light source emits red light with the wavelength of 600nm to 760nm and the illumination dosage of the red light source is 1J/cm 2 To 50J/cm 2 The composition comprises biotin and tripeptide-1; the present application has the effect of synergistically promoting collagen i synthesis by combining potent actives (biotin and tripeptide-1) with low energy red light (LLLT). Meanwhile, due to the increase of the synthesis amount of the collagen I, the combination can achieve the effects of plumping skin, fixing hair, preventing hair loss and resisting aging, thereby illustrating the effects of the application method of combining LLLT with biotin+tripeptide-1 on resisting aging and preventing hair loss;
(2) The efficacy active (biotin and tripeptide-1) and low energy red light (LLLT) combination also has synergistic ATP release promoting effects, with ATP release levels that are higher than both LLLT alone and efficacy active alone. The increase of the ATP release amount can increase the cell energy to a certain extent, promote the cell metabolism and give more energy to cells for collagen synthesis and the like, thereby delaying aging and increasing the number of hair follicles, and further showing that the combination of low-energy red light and efficacy active substances has a synergistic effect on anti-aging and anti-alopecia.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described below, it being obvious that the drawings in the following description are only some embodiments of the present application, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing comparison of the amounts of collagen I synthesized in the experimental cell test in the examples of the present application;
FIG. 2 is a graph showing fluorescence contrast of the synthesis amount of collagen I in the experimental cell test in the example of the present application;
FIG. 3 is a graph showing comparison of ATP release amounts in cell assay tests in the examples of the present application.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the present application will be further described in detail with reference to the accompanying drawings and examples. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the present application.
Skin care products containing collagen components or components promoting collagen synthesis and cosmetic devices using acousto-optic and electric heating such as micro-current, radio frequency, low energy red light (LLLT) are common topical methods of supplementing collagen and promoting collagen synthesis. However, in the prior art, the skin care product/component or the cosmetic device is usually used alone to achieve the effect of collagen synthesis, and few instruments and skin care products are matched to verify the synergistic effect of the two in collagen synthesis, which limits the upper limit value of collagen synthesis of the product. Thus, there is no combination of components for stimulating collagen synthesis and instrument matching.
In order to solve the above technical problems, an embodiment of the present application provides a care method for synergistic interaction of red light and a composition, the care method includes: applying the composition to a care area; illuminating the care area with a red light source; wherein the composition comprises biotin and tripeptide-1.
The red light source in the nursing method is used as a physical device, biotin and tripeptide-1 are used as efficacy raw materials, and the red light source and the efficacy raw materials are combined, so that the nursing method has the effects of synergistically improving collagen I synthesis and synergistically promoting ATP release. In the application, the ATP release promoting amount is the ATP generation promoting amount, so that the intracellular ATP content is increased, the ATP in the cells is the expression of cell energy, the ATP release increasing amount shows that the respiration of the cells is enhanced, the energy in the cells is increased, that is, more energy in the cells participates in collagen synthesis, and further the effects of delaying aging (anti-aging) and increasing the number of hair follicles (anti-hair loss) are achieved, and the combined system can be applied to the fields of personal care, oral cavity, anti-hair loss, hair growth and the like.
In some embodiments, the biotin and tripeptide-1 are present in an amount of 0.01wt% to 20wt% based on the total weight of the composition.
Illustratively, the biotin and tripeptide-1 are present in an amount ranging from any two of 0.01wt%, 0.1wt%, 1wt%, 3wt%, 5wt%, 8wt%, 10wt%, 15wt%, 20wt%, based on the total weight of the composition.
In some embodiments, the biotin and tripeptide-1 are present in an amount of 0.1wt% to 7wt% based on the total weight of the composition.
Illustratively, the biotin and tripeptide-1 are present in an amount ranging from any two of 0.1wt%, 0.5wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, based on the total weight of the composition.
In some embodiments, the mass concentration ratio of biotin to tripeptide-1 is 1 (0.3-3).
Illustratively, the mass concentration ratio of biotin to tripeptide-1 is in the range of any two values of 1:0.3, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3.
In some embodiments, the mass concentration ratio of biotin to tripeptide-1 is 1:1.
in some embodiments, the wavelength of the red light source is 600nm to 760nm; the illumination dosage of the red light source is 1J/cm 2 To 50J/cm 2 。
Illustratively, the red light source has a wavelength in the range of any two values of 600nm, 620nm, 640nm, 680nm, 700nm, 720nm, 740nm, 760nm;
illustratively, the illumination dose of the red light source is 1J/cm 2 、5J/cm 2 、10J/cm 2 、20J/cm 2 、30J/cm 2 、40J/cm 2 、50J/cm 2 A range of any two values.
In some embodiments, the wavelength of the red light source is 600nm to 660nm; the illumination dosage of the red light source is 1J/cm 2 To 20J/cm 2 。
Illustratively, the red light source has a wavelength in the range of any two values of 600nm, 610nm, 630nm, 650nm, 660nm;
illustratively, the illumination dose of the red light source is 1J/cm 2 、2J/cm 2 、4J/cm 2 、6J/cm 2 、8J/cm 2 、10J/cm 2 、14J/cm 2 、16J/cm 2 、18J/cm 2 、20J/cm 2 A range of any two values.
In some embodiments, the obtaining device of the red light source comprises at least one of an LED generating device and a laser generating device.
Specifically, in one example, the obtaining device of the red light source is an LED (light emitting diode) generating device, in another example, the obtaining device of the red light source is a laser generating device, or in other examples, the obtaining device of the red light source includes an LED generating device and further includes a laser generating device.
In a second aspect, embodiments of the present application provide a red light and composition synergistic care system comprising a red light source and a composition; the combination system is used to implement any of the care methods described above.
In a third aspect, embodiments of the present application provide the use of the care method of any one of the above or the care system of any one of the above in skin care, hair loss prevention, hair growth, and oral care.
In some embodiments, if the method of care or the care system is applied to skin care, the composition is present in any one of a lotion, a concentrate, an emulsion, a cream, or a mask;
if the method of care or the system of care is applied to anti-hair loss and hair growth, the composition is present in any of a shampoo, a conditioner, scalp essence, or scalp spray;
if the method of care or the care system is applied to oral care, the composition is in any of a toothpaste, a dentifrice, a mouthwash, an oral spray, an oral dressing, or an oral gel.
In a fourth aspect, embodiments of the present application provide the use of a method of care as described in any one of the above or a care system as described in any one of the above to promote synthesis of collagen I.
In a fifth aspect, the present application provides the use of a combination system as described in any one of the preceding claims to facilitate the production of ATP.
There is no sequence of two steps in the care method described in the embodiments of the present application, for example:
applying the composition to a care area and irradiating the care area with a red light source; or,
irradiating the care area with a red light source, and coating the composition on the care area; or,
the composition is applied to a care area while the care area is irradiated with a red light source.
Illustratively, the compositions will contain (biotinAnd tripeptide-1) is coated on the area to be treated, and red light with the wavelength of 600nm to 760nm is emitted by a red light source with the irradiation dose of 1J/cm 2 To 50J/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the Or,
the red light with the wavelength of 600nm to 760nm is emitted by a red light source to be firstly irradiated on the area to be coated, wherein the irradiation dose of the red light source is 1J/cm 2 To 50J/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the Applying a fluid, pasty or solid substance containing the composition (biotin and tripeptide-1) to the area to be treated; or,
applying a fluid, paste or solid substance containing a composition (biotin and tripeptide-1) to the area to be treated, while directly irradiating the area to be treated with red light having a wavelength of 600nm to 760nm emitted from a red light source having a dose of 1J/cm 2 To 50J/cm 2 。
Preferably, a fluid, paste or solid substance containing the composition (biotin and tripeptide-1) is applied to the area to be treated, and red light having a wavelength of 600nm to 660nm is emitted by a red light source having a dose of 1J/cm directly irradiated on the area to be treated 2 To 20J/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the Or,
the red light with the wavelength of 600nm to 660nm is emitted by a red light source to be firstly irradiated on the area to be coated, wherein the irradiation dose of the red light source is 1J/cm 2 To 20J/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the Applying a fluid, pasty or solid substance containing the composition (biotin and tripeptide-1) to the area to be treated; or,
applying a fluid, paste or solid substance containing a composition (biotin and tripeptide-1) to the area to be treated, while directly irradiating the area to be treated with red light having a wavelength of 600nm to 660nm emitted from a red light source having an irradiation dose of 1J/cm 2 To 20J/cm 2 。
Example 1
A skin care product comprising the following components in percentage by mass: 0.01 to 20 percent of biotin + tripeptide-1, 0.01 to 20 percent of other skin care active substances, 0.1 to 10 percent of emulsifying agent, 1 to 10 percent of humectant, 0.1 to 70 percent of polyalcohol, 0 to 10 percent of thickening agent, 0 to 5 percent of thickening stabilizer, 0 to 3 percent of foaming agent, 2 to 20 percent of emollient, 0 to 2 percent of antioxidant, 0 to 0.1 percent of pH regulator, 0 to 0.1 percent of chelating agent, 0.1 to 1 percent of preservative, 0 to 10 percent of ethanol and the balance of deionized water.
Wherein the other skin care actives include one or more of resveratrol, catechin, snake venom tripeptide, acetyl hexapeptide-1, palmitoyl tripeptide-5, ergothioneine, nicotinamide, bisabolol, amino acids, or boscalid; the emulsifier comprises one or more of glycerol stearate, cetostearyl alcohol polyether-12, cetostearyl alcohol polyether-20, polyglycerol-6 distearate, polyethylene glycol-40, stearyl alcohol, polysorbate-60, sorbitan stearate, glycerol caprylate, polyethylene glycol-8, polysorbate-20 or glycerol polyether-26; the humectant comprises one or more of glycerin, hyaluronic acid, sodium hyaluronate, allantoin, mannitol, glyceroglycoside or sodium PCA; the polyol comprises one or more of butanediol, propylene glycol, 1, 3-propanediol, 1, 2-pentanediol or 1, 2-hexanediol; the thickener comprises one or more of xanthan gum, carbomer, poloxamer, cellulose gum, cetyl alcohol, arachidyl alcohol, behenyl alcohol or dextrin; the thickening stabilizer comprises one or more of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, acrylic acid (ester) or C10-30 alkanol acrylate cross-linked polymer or glycerol stearate; the foaming agent comprises one or more of cetyl alcohol, sodium methyl hard acyl taurate, lauryl glucoside or cocamidopropyl betaine; the emollient comprises one or more of jojoba seed oil, cetostearyl isononanoate, cetyl palmitate, squalane, cholesterol isostearate, shea butter fruit ester, isononyl isononanoate or behenyl alcohol; the antioxidant comprises one or more of nicotinamide, p-hydroxyacetophenone, vitamin E, tocopheryl acetate or butylated hydroxytoluene; the pH regulator comprises one or more of citric acid, succinic acid, tromethamine, lactic acid, potassium hydroxide or triethanolamine; the chelating agent comprises one or more of EDTA-disodium or EDTA-tetrasodium; the preservative comprises one or more of methylparaben, sodium benzoate, benzoic acid, sorbic acid, phenoxyethanol or potassium sorbate.
Example 2
A hair loss preventing and growing product comprises the following components in percentage by mass: 10.01 to 20 percent of biotin + tripeptide-10.01 to 20 percent of other active substances with anti-hair-loss and hair-growing effects, 0.1 to 10 percent of emulsifying agent, 1 to 10 percent of humectant, 0.1 to 70 percent of polyalcohol, 0 to 10 percent of thickening agent, 0 to 5 percent of thickening stabilizer, 0 to 3 percent of foaming agent, 0 to 0.5 percent of cooling agent, 0 to 0.1 percent of chelating agent, 0 to 2 percent of antioxidant, 0.1 to 1 percent of preservative, 0 to 8 percent of ethanol and the balance of deionized water.
Wherein the other anti-hair loss and hair growth promoting active substances comprise one or more of diaminopyrimidine oxide, acetyl tetrapeptide-3, myristyl pentapeptide-4, nicotinamide, ginkgo extract, lindera root extract, cacumen Platycladi extract, ginseng extract, polygonum multiflorum extract, oleanolic acid, lavender extract or rosemary extract; one or more of menthol, borneol or mint extracts as cooling agents. The optional ranges for the other components are the same as in example 1.
Example 3
An oral care product comprising the following components in mass percent: 10.01 to 20 percent of biotin + tripeptide-10.01 to 20 percent of other oral cavity efficacy active substances, 0.1 to 10 percent of surfactant, 1 to 10 percent of humectant, 0 to 10 percent of thickening agent, 0 to 5 percent of foaming agent, 0 to 30 percent of friction agent, 0.01 to 5 percent of sweetener, 0.01 to 0.5 percent of cooling agent, 0.01 to 0.5 percent of oral cavity antibacterial agent, 0.1 to 2 percent of pH regulator, 0.1 to 1 percent of preservative, 0 to 1 percent of essence or essential oil and the balance of deionized water.
Wherein the other oral efficacy actives include one or more of honeysuckle extract, dipotassium glycyrrhizinate, tranexamic acid, paeonol, sodium monofluorophosphate, titanium dioxide, sodium bicarbonate, probiotics or enzymes; the surfactant comprises one or more of polyethylene glycol-8, polyethylene glycol 400 and PEG-40 hydrogenated castor oil; the humectant comprises one or more of sorbitol, glycerol, hyaluronic acid or allantoin; the thickener comprises one or more of cellulose gum or xanthan gum; the foaming agent comprises one or more of sodium lauryl sulfate, sodium lauroyl sarcosinate or cocamidopropyl betaine; the friction agent comprises one or more of hydrated silica or hydroxyapatite; the sweetener comprises one or more of saccharin sodium, sucralose, xylitol or trichlorogalactose; the cooling agent comprises one or more of menthol, borneol or mint extracts; the oral bacteriostat comprises one or more of zinc citrate, cymene or triclosan; the essence or essential oil comprises one or more of synthetic essence or plant essential oil. Alternative ranges for the other components are the same as in example 1 and/or example 2.
The present application is further illustrated by the following examples.
Example 1
Red light dosage is 10J/cm 2 The LED instrument with the wavelength of 635nm is matched with the emulsion with the skin anti-aging effect, wherein the emulsion with the skin anti-aging effect comprises the following components in percentage by mass:
glycerol 5%, butylene glycol 3%, sodium hyaluronate 0.1%, vitamin E0.5%, snake venom tripeptide 0.5%, xanthan gum 0.5%, jojoba seed oil 1.0%, squalane 1.0%, cetyl alcohol 0.1%, glyceryl stearate 0.5%, cetostearyl alcohol isononanoate 3%, cetyl alcohol palmitate 4%, cetostearyl alcohol polyether-12.1%, cetostearyl alcohol polyether-20.2%, sodium benzoate 0.1%, 1, 2-pentanediol 0.5%, EDTA-disodium 0.1%, biotin 3%, tripeptide-1 3%, and deionized water in balance.
The preparation method of the emulsion comprises the following steps:
according to the raw material formulation, (a) oily component (vitamin E0.5%, jojoba seed oil 1.0%, squalane 1.0%, cetyl alcohol 0.1%, glyceryl stearate 0.5%, cetostearyl alcohol isononanoate 3%, cetyl alcohol palmitate 4%, cetostearyl alcohol polyether-12%, cetostearyl alcohol polyether-20%) and (b) aqueous component (deionized water, glycerin 5%, butylene glycol 3%, sodium hyaluronate 0.1%, sodium benzoate 0.1%, 1, 2-pentanediol 0.5%, EDTA-disodium 0.1%,) were heated to 75 ℃ respectively; the oily component is then drawn into the aqueous component to form a mixed liquor (c).
The mixed solution (c) was homogenized in a homogenizer for 5 minutes at 2900rpm, and cooled by turning on cooling water under slow stirring. Cooling the mixed solution (c) to 45 ℃, adding 0.5% of xanthan gum, and fully and uniformly stirring to form a mixed solution (d); adding tripeptide of snake venom 0.5%, biotin 3% and tripeptide-1 3% into the mixed solution (d), stirring thoroughly to form a mixed solution (e), stirring slowly, cooling to 35 deg.C, and discharging.
Example 2
Red light dosage is 2J/cm 2 The scalp essence with the hair loss prevention and hair growth effects is matched with a laser instrument with the wavelength of 650nm, wherein the scalp essence with the hair loss prevention and hair growth effects comprises the following components in percentage by mass:
biotin 3%, tripeptide-1 3%, diaminopyrimidine oxide 2%, cacumen Platycladi extract 1%, semen Ginkgo extract 1%, sodium hyaluronate 0.5%, glycerol 1%, vitamin E0.5%, xanthan gum 0.5%, polyethylene glycol-40%, propylene glycol 2%, ethanol 3%, polysorbate-20.5%, stearyl alcohol 0.5%, menthol 0.1%, EDTA-disodium 0.05%, sodium benzoate 0.5%, and deionized water in balance.
Wherein the extract of the biota orientalis is a material with a commodity name of biota orientalis extract provided by Shanghai children biotechnology limited company as a manufacturer;
the ginkgo extract is a material with the commodity name of ginkgo extract provided by Shanghai, biological technology Co., ltd.
The preparation method of the scalp essence comprises the following steps:
according to the raw materials of the scalp essence, 1% of cacumen biotae extract, 1% of ginkgo extract, 0.5% of sodium hyaluronate, 1% of glycerol, 3% of ethanol, 2% of propylene glycol, 0.05% of EDTA-disodium, 0.5% of sodium benzoate and deionized water are mixed and stirred at 75 ℃ to form a mixed solution a;
mixing vitamin E0.5%, polyethylene glycol-40% 1%, polysorbate-20.5%, stearyl alcohol 0.5% and menthol 0.1%, and stirring at 75deg.C to obtain mixed solution b;
then pouring the mixed solution b into the mixed solution a to form mixed solution c;
the mixture c was homogenized in a homogenizer for 3 minutes at a homogenizing speed of 3000rpm. Then cooling by starting cooling water under slow stirring (30 rpm); cooling the mixed solution c to 45 ℃, adding 0.5% of xanthan gum and 2% of diaminopyrimidine oxide, and fully and uniformly stirring to form a mixed solution d;
adding 3% of biotin and 1 3% of tripeptide into the mixed solution d, fully and uniformly stirring to form a mixed solution e, slowly stirring, cooling to 35 ℃ and discharging.
Example 3
Red light dosage is 5J/cm 2 The LED instrument with the wavelength of 635nm is matched with the mouthwash with the oral cavity anti-aging effect, wherein the mouthwash with the oral cavity anti-aging effect comprises the following components in percentage by mass:
2% of biotin, 1 2% of tripeptide, 0.1% of honeysuckle extract, 4% of glycerol, 1% of PEG-40 hydrogenated castor oil, 1% of xylitol, 0.03% of cymene, 0.05% of menthol, 0.02% of sucralose, 0.1% of citric acid, 0.5% of sodium benzoate, 0.05% of rose essential oil and the balance of deionized water.
The preparation method of the mouthwash comprises the following steps:
according to the raw materials of the mouthwash, 2% of biotin, 1 2% of tripeptide, 0.1% of honeysuckle extract, 4% of glycerol, 1% of xylitol, 0.03% of cymene, 0.02% of sucralose, 0.5% of sodium benzoate and deionized water are mixed, and stirred at 400rpm at room temperature to form a mixed solution a;
mixing 1% of PEG-40 hydrogenated castor oil, 0.05% of menthol and 0.05% of rose essential oil, and stirring at 400rpm at 80 ℃ to form a mixed solution b;
pouring the mixed solution b into the mixed solution a, stirring at 400rpm at 80 ℃ and completely mixing the two phases to form a mixed solution c;
and adding 0.1% of citric acid into the mixed solution c, adjusting the pH value to 6.5, continuously stirring for 1 hour, and cooling to obtain a mouthwash sample.
The technical effects of the present application are further illustrated by the following cell experimental tests.
Collagen I test experimental grouping information
Cell experiment test method (Sample refers to Sample/counter):
(1) Collagen I synthesis amount detection:
1) Day 0, cells were seeded: incubate in incubator for 24h.
2) Liquid change on day 1: BC (blank), LLLT groups replaced DMEM medium; the Sample/counter and Sample/counter + LLLT groups were replaced with fresh medium containing 0.15mg/mL Sample, respectively, and incubation was continued for 24h in the incubator.
2) Irradiation of cells on day 2: and taking out the corresponding pore plate from the incubator, and uncovering the cell when the cell is irradiated by the sterile operation table. After the irradiation, the well plate was buckled and returned to the incubator (37 ℃, 5% CO) 2 95% rh) was incubated for 24h.
3) Cells were fixed with 4% paraformaldehyde after the end of post-incubation.
4) Cells fixed with 4% paraformaldehyde were subjected to immunofluorescent staining to detect the synthesis amount of collagen I and photographed under a fluorescent microscope.
5) Data analysis: the collagen I production of the BC group is normalized to 100%, and the data of other groups are converted according to the normalization principle to obtain the normalized percentage value of the collagen I production. The increase in collagen I production from each experimental group relative to the BC group was obtained by subtracting the BC group from each experimental group, and the data were compared by histogram. Each set of experiments had 3 replicates, ensuring that the data was statistically significant.
The bar graph of the detection result is shown in fig. 1, and the photograph under the fluorescence microscope is shown in fig. 2.
Test results showed that the increase in the synthesis amount of collagen I (type I collagen) under the condition of increasing LLLT only was 399% with BC group as a reference standard; taking BC group as a reference standard, the lifting amount of the synthesis amount of the collagen I under the condition of only increasing biotin+tripeptide-1 is 184%; when biotin+tripeptide-1 was combined with LLLT, the amount of increase in collagen I synthesis was 531% (p-value 0.0027) using BC group as a reference, which was 1.3 times that of single LLLT, 2.9 times that of single biotin+tripeptide-1; meanwhile, as shown in FIG. 2, the biotin+tripeptide-1+LLLT group has the strongest fluorescence intensity. It can be seen that the combination of biotin + tripeptide-1 and LLLT has a synergistic effect on the synthesis of collagen I.
In FIG. 1, the increase in the synthesis amount of collagen I (type I collagen) under the condition of increasing LLLT alone was 399% based on the BC group as a reference standard; the increase in collagen I synthesis was 81% with the BC group as a reference, with only an increase in arginine/lysine polypeptide (counter example 1); when arginine/lysine polypeptides were combined with LLLT, the increase in collagen I synthesis was 29% using BC panels as a reference, which was lower than that of single LLLT. It was demonstrated that arginine/lysine polypeptides combined with LLLT did not produce a synergistic effect in collagen I synthesis.
In FIG. 1, the increase in the synthesis amount of collagen I (type I collagen) under the condition of increasing LLLT alone was 399% based on the BC group as a reference standard; taking BC group as a reference standard, the improvement of the synthesis amount of collagen I under the condition of only increasing vitamin C (counter example 2) is 79 percent; when vitamin C was combined with LLLT, the increase in collagen I synthesis was 181% with the BC group as a reference, which is lower than that of LLLT alone. It was demonstrated that vitamin C combined with LLLT and did not produce a synergistic effect in collagen I synthesis.
Cell ATP test experimental grouping information
Cellular ATP test method (samples all refer to Sample/counter):
1) Day 0, cells were seeded: incubate in incubator for 24h.
2) Liquid change on day 1: the BC group and the LLLT group are respectively replaced with DMEM culture medium; the Sample/counter and Sample/counter + LLLT groups were replaced with fresh medium containing 0.15mg/mL efficacy active (biotin + tripeptide-1), respectively, and incubation was continued for 24h in the incubator.
3) Irradiation of cells on day 2: and taking out the corresponding pore plate from the incubator, and uncovering the cell when the cell is irradiated by the sterile operation table. After the irradiation is finished, the pore plate is buckled and put back into the incubator for incubation for 6 hours.
4) After the post incubation, the ATP release was detected.
5) ATP release amount detection method: detection was performed according to the protocol of the enhanced ATP assay kit.
7) And (5) data analysis. The ATP release amount of the BC group is normalized to 100%, and the data of other groups are converted according to the normalization principle to obtain the normalized percentage value of the ATP release amount. The ATP release increase amount of each group relative to the BC group was obtained by subtracting the BC group from each of the sample group, the sample+lllt group, and the LLLT group, and the data were compared by histogram. Each set of experiments had 3 replicates, ensuring that the data was statistically significant.
The comparison of the amounts of ATP released from the columns of the assay results is shown in FIG. 3.
Test results show that the condition of only increasing LLLT can increase the ATP release amount by 15.38% by taking BC group as a reference standard; the BC group is used as a reference standard, and the condition of only increasing biotin and tripeptide-1 improves the release amount of ATP by 9.23%; when conditions of both LLLT and biotin+tripeptide-1 were increased, the ATP release rate was increased by 30.77% (p-value 0.0398) using BC group as a reference, which was 2-fold that of the single LLLT condition and 3.3-fold that of the single biotin+tripeptide-1 condition. Indicating that biotin + tripeptide-1 combined with LLLT produces a synergistic effect in terms of ATP release.
In FIG. 3, using BC group as reference standard, increasing LLLT alone can increase ATP release by 15.38%; with BC group as reference standard, increasing only the condition of acetyl tetrapeptide-3 (counter example 1) reduced the ATP release by 18.46%; when conditions for increasing both LLLT and acetyl tetrapeptide-3 were increased, the ATP release was increased by only 9.23% using BC panels as a reference, which is even lower than that of single LLLT. Indicating that acetyl tetrapeptide-3 combines with LLLT and does not produce a synergistic effect in terms of ATP release.
In FIG. 3, using BC group as reference standard, increasing LLLT alone can increase ATP release by 15.38%; with the BC group as a reference standard, the condition of only increasing the radix linderae extract (counter example 2) reduces the ATP release by 36.92%; when conditions for increasing both LLLT and lindera root extract were increased, the ATP release was increased by only 4.62% with BC group as a reference standard, which is even lower than that of single LLLT. It was demonstrated that the combination of lindera root extract with LLLT did not produce a synergistic effect in terms of ATP release.
The collagen I detection method of the cell experiment is used for detecting the collagen I production of different groups, and the combination of the biotin, the tripeptide-1 and the LLLT has higher collagen I synthesis, so that the combination of low-energy red light (LLLT) and the biotin, the tripeptide-1 has the effect of synergistically promoting the collagen I synthesis. Due to the increase of the synthesis amount of the collagen I, the combination can achieve the effects of plumping skin, fixing hair, preventing hair loss and resisting aging, thereby demonstrating the effects of the application method of combining low-energy red light (LLLT) with biotin and tripeptide-1 on resisting aging and preventing hair loss.
In addition, the biotin+tripeptide-1+ efficacy active substance has the effect of synergistically promoting the release of ATP, the ATP release amount of the biotin+tripeptide-1 is higher than that of single LLLT and single biotin+tripeptide-1, and the increase of the ATP release amount can increase cell energy to a certain extent, promote cell metabolism, give more energy to cells for collagen synthesis and the like, so that the effects of delaying aging and increasing the number of hair follicles are achieved, thus the combination of low-energy red light and efficacy active substances has the synergistic effect on anti-aging and anti-alopecia; in the application of the product, the anti-aging and anti-drop capabilities of the low-energy red light equipment matched with the product containing the functional active substances are higher than those of the single low-energy red light equipment or the single functional active substances, and the upper limit of the anti-aging and anti-drop capabilities of the existing product is effectively improved through the synergistic effect.
The foregoing description of the preferred embodiments of the present application is not intended to be limiting, but is intended to cover any and all modifications, equivalents, and alternatives falling within the spirit and principles of the present application.
Claims (10)
1. A method of care for a synergistic effect of red light and a composition, the method comprising:
applying the composition to a care area;
illuminating the care area with a red light source;
wherein the composition comprises biotin and tripeptide-1.
2. The method of care according to claim 1, wherein the biotin and tripeptide-1 are present in an amount of 0.01 to 20 wt. -%, based on the total weight of the composition;
preferably, the biotin and tripeptide-1 are present in an amount of 0.1wt% to 7wt% based on the total weight of the composition.
3. The method of claim 1, wherein the mass concentration ratio of biotin to tripeptide-1 is 1: (0.3-3);
preferably, the mass concentration ratio of the biotin to the tripeptide-1 is 1:1.
4. the method of claim 1, wherein the wavelength of the red light source is 600nm to 760nm, and the illumination dose of the red light source is 1J/cm 2 To 50J/cm 2 ；
Preferably, the wavelength of the red light source is 600nm to 660nm, and the illumination dosage of the red light source is 1J/cm 2 To 20J/cm 2 。
5. The method of care of claim 1, wherein the obtaining means for a red light source comprises at least one of an LED generating means and a laser generating means.
6. A red light and composition synergistic care system, wherein the care system comprises a red light source and a composition;
the combination system is for implementing the care method of any one of claims 1 to 5.
7. Use of the care method according to any one of claims 1 to 5 or the care system according to claim 6 for skin care, hair growth, oral care.
8. The use according to claim 7, wherein,
if the care method or the care system is applied to skin care, the composition is present in any one of a lotion, a serum, an emulsion, a cream, or a mask;
if the method of care or the system of care is applied to anti-hair loss and hair growth, the composition is present in any of a shampoo, a conditioner, scalp essence, or scalp spray;
if the method of care or the care system is applied to oral care, the composition is in any of a toothpaste, a dentifrice, a mouthwash, an oral spray, an oral dressing, or an oral gel.
9. Use of the care method according to any one of claims 1 to 5 or the care system according to claim 6 for promoting the synthesis of collagen I.
10. Use of the care method of any one of claims 1 to 5 or the care system of claim 6 to promote ATP production.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211195119.XA CN117618277A (en) | 2022-09-27 | 2022-09-27 | Nursing method, nursing system and application of synergistic effect of red light and composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211195119.XA CN117618277A (en) | 2022-09-27 | 2022-09-27 | Nursing method, nursing system and application of synergistic effect of red light and composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117618277A true CN117618277A (en) | 2024-03-01 |
Family
ID=90015287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211195119.XA Pending CN117618277A (en) | 2022-09-27 | 2022-09-27 | Nursing method, nursing system and application of synergistic effect of red light and composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117618277A (en) |
-
2022
- 2022-09-27 CN CN202211195119.XA patent/CN117618277A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769698B (en) | A kind of cosmetic composition and its application without preservative | |
| AU2002309036B2 (en) | Preparation for hair and/or scalp | |
| JP4488560B2 (en) | Cosmetic composition containing moisturizing plant extract | |
| JP4280341B2 (en) | Cosmetic composition containing moisturizing plant extract | |
| JPWO2004071472A1 (en) | External preparation for skin comprising a carbohydrate derivative of α, α-trehalose | |
| JP2012041302A (en) | Skin cosmetic | |
| JP2000191498A (en) | Collagen production facilitative agent and preparation for external use for skin | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| JPH07277939A (en) | Skin external preparation | |
| JP4179971B2 (en) | Moisturizing plant extract and external preparation, cosmetic, bath preparation and detergent containing the extract | |
| JP4101106B2 (en) | Moisturizing plant extract and external preparation, cosmetic, bath preparation and cleaning agent containing the extract | |
| US20220233440A1 (en) | Nano- or micro-emulsion compositions and methods of use thereof | |
| JP4551053B2 (en) | Moisturizing plant extract and moisturizing external preparation, cosmetic, bath preparation and detergent composition containing the extract | |
| CN108524354A (en) | Skin care compositions, facial treatment mask and preparation method thereof | |
| KR20060014433A (en) | Novel dermatological composition | |
| US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| JP4921732B2 (en) | Melanin synthesis promoter and topical skin preparation | |
| JPH09183718A (en) | Composition suitable for external application | |
| KR101547758B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| JP3881411B2 (en) | Composition suitable for external use | |
| CN109453088B (en) | Whitening and firming cream, preparation method thereof and tyrosinase inhibitor | |
| CN117618277A (en) | Nursing method, nursing system and application of synergistic effect of red light and composition | |
| JP5429851B2 (en) | Active oxygen scavenger, skin external preparation and cosmetic using the active oxygen scavenger | |
| CN117643547A (en) | Nursing method, nursing system and application for promoting ATP production by cooperation of red light and composition | |
| JPH1095704A (en) | Composition suitable for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |